Formulary & Coverage

Merck's Oral PCSK9 Inhibitor Approval Undercuts Injectables

Merck's Oral PCSK9 Inhibitor Approval Undercuts Injectables

George Padron
Specialty Medicine, Healthcare Headlines, FDA & Regulations, Cardiology, Access & Affordability, Prior Authorization, Managed Care, Formulary & Coverage, Pharmacy Benefit Trends | Jul 17, 2026
FDA has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, priced at $315 per month. Merck has positioned it below injectable options, transitioning PCSK9 medications into retail pharmacies.
Load More
Only Healthcare Today Covering Clinical Healthcare, Access and Cost

Only Healthcare Today
Covering Clinical Healthcare, Access and Cost

1 Hewitt Square, Suite 139
East Northport, NY 11731

Who We Are


About Us Editorial Policy Contributors & Partners

Connect


Contact Us Work With Us Advertising Terms of Use Privacy Policy